CAMBRIDGE, Mass.— Insilico Medicine, a clinical-stage artificial intelligence-driven drug discovery company, has raised $110 million in a Series E financing round led by a private equity fund of Value Partners Group, one of Asia’s largest independent asset management firms.
The round saw strong participation from new industry- and technology-focused investors, along with continued backing from existing supporters, the company announced Thursday.
Insilico said the funding will support advancements in its AI platform and drug development pipeline. Investments will focus on refining AI models and expanding automation in its R&D processes, including updates to its automated laboratory. The company also plans to accelerate the clinical validation of its flagship candidate for idiopathic pulmonary fibrosis and further develop additional drug programs, both independently and in collaboration with partners.
“We are excited to partner with Insilico Medicine in its mission to transform drug discovery with AI and automation,” said Dr. Chuen Yan Leung, a partner specializing in healthcare investments at Value Partners. “Insilico’s advancements will not only accelerate the development of life-saving therapies but also redefine the future of biopharmaceutical R&D.”
Insilico CEO and founder Alex Zhavoronkov called the oversubscribed funding round a “key milestone” that reflects investor confidence in the company’s AI-driven approach.
“The funds raised will accelerate the advancement of our drug pipeline and AI platform, further solidifying Insilico’s leadership in this rapidly evolving sector,” Zhavoronkov said. “We remain dedicated to our mission of extending productive longevity and are proud to be at the forefront of healthcare innovation.”
Since its last financing round, Insilico has made significant progress in AI-powered drug discovery. The company’s proprietary AI platform, Pharma.AI, has helped reduce the average time to select a preclinical candidate to 12-18 months—down from the 2.5 to 4 years typically required. The platform, which receives major updates twice a year, integrates generative AI across biology, chemistry, and clinical research.
Insilico has also introduced new AI tools, including Nach01, a multimodal model for chemical and natural language processing, and Dora, a multi-agent generative research assistant. The company recently deployed its first humanoid AI scientist within its fully robotic laboratory, Life Star1, which is connected to Pharma.AI.
The company’s pipeline includes 30 AI-discovered drug assets, with 10 receiving investigational new drug (IND) clearance. Its most advanced candidate, Rentosertib, developed for idiopathic pulmonary fibrosis, has shown positive results in multiple clinical studies, including a Phase IIa trial where it demonstrated favorable safety and dose-dependent efficacy.
Insilico has also built a revenue stream through out-licensing agreements, securing four deals collectively valued at more than $2.1 billion with partners including Fosun Pharma, Exelixis, and Menarini. The company has also formed drug development collaborations with firms such as Sanofi, Saudi Aramco, and Therasid Bioscience, totaling over $1.4 billion.
With its latest round of funding, Insilico said it will continue to expand its AI-powered drug discovery efforts and strengthen collaborations across the biopharmaceutical industry.
